The U.S. Food and Drug Administration (FDA) announced the approval of Tagrisso (osimertinib) as the first adjuvant treatment for patients with non-small cell lung cancer whose tumors have a specific type of genetic mutation.
In the overall clinical trial population, patients who received Tagrisso had an 80 percent decrease in disease recurrence chance compared with patients who received a placebo, stated the FDA.
Read More
